Jodie Pope Morrison
CIK 1618247 · CEO · last filed 2026-07-20
Jodie Pope Morrison is a CEO who has filed 32 SEC Form 4 insider transactions across 7 companies since 2014. The most recent filing, for QTTB, was dated Jul 20, 2026. Across all open-market trades the lifetime net is −$533.8K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $5.7M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$5.68M
7
32
-$533.8K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| QTTB | CEO | 353,104 | $15.95 | $5.63M | -$141.4K | 7 | 2026-07-20 |
| Verve Therapeutics, Inc. (VERV) Delisted | Director | — | $11.13 | — | $0 | 3 | 2025-07-28 |
| Rein Therapeutics, Inc. (ALRN) Delisted | Director | — | $2.11 | — | $0 | 6 | 2022-06-17 |
| AKBA | Director | 58,619 | $0.86 | $50.4K | $0 | 2 | 2019-06-10 |
| KERYX BIOPHARMACEUTICALS INC (KERX) Delisted | Interim CEO | 0 | — | — | $0 | 5 | 2018-12-13 |
| Eledon Pharmaceuticals, Inc. (NVUS) Delisted | Director | — | — | — | $0 | 1 | 2017-07-05 |
| Eledon Pharmaceuticals, Inc. (TKAI) Delisted | President and CEO | 4,174 | — | — | -$392.4K | 7 | 2016-01-08 |
Recent Filings
32 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-20 | QTTB | Grant (A) | +132,000 | $0 | EDGAR |
| 2026-03-20 | QTTB | Grant (A) | +132,000 | $0 | EDGAR |
| 2026-02-27 | QTTB | Sell (S) | −9,896 | -$44.7K | EDGAR |
| 2025-12-04 | QTTB | Sell (S) | −22,506 | -$77.9K | EDGAR |
| 2025-12-02 | QTTB | Notice (144) | −22,506 | -$77.9K | EDGAR |
| 2025-08-28 | QTTB | Sell (S) | −10,494 | -$18.9K | EDGAR |
| 2025-07-28 | Verve Therapeutics, Inc. (VERV) Delisted | Disp (D) | — | $0 | EDGAR |
| 2025-06-06 | Verve Therapeutics, Inc. (VERV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-02-26 | QTTB | Mixed | +132,000 | $0 | EDGAR |
| 2024-06-28 | Verve Therapeutics, Inc. (VERV) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.